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Need for chemoprophylaxis for travelers to the Americas:
Yes
P. Arguin
CDC, Atlanta, GA, USA
International travelers may sometimes acquire infectious
diseases such as malaria during their journeys. This session
will be a debate about the usefulness of malaria chemopro-
phylaxis for travel to the Americas. Malaria can be a fatal
disease even when it is diagnosed early and treated cor-
rectly. It is preferable for persons at risk of infection with
malaria to prevent the infection.
doi:10.1016/j.ijid.2010.02.1536
19.003
Need for Continuous Prophylaxis for Travelers to the
Americas: No
M. Boulos
University of Sao Paulo, Sao Paulo, Brazil
The risk a traveler becomes infected by malaria will
depend on the overall rate of malaria transmission in the
area to be visited and the extension of the traveler’s contact
with infected mosquitoes.
Topics like: 1. Wearing long-sleeve shirts and long
trousers; 2. Applying insect repellent; 3. Spraying
aerosolized insecticides in living and sleeping places;
4. Sleeping in a screened or airconditioned rooms; 5.
Sleeping on netted bed; and 6. Use mosquito coils con-
taining pyrethroids are consensual measures in all malaria
transmission areas, and the use of chemoprophylaxis are
not consensual in low endemic areas (Wyler, NEJM 1993)
My aim is convincing you that the routinely use of malaria
chemoprophylaxis is not needed in America.
The use of anti-malarial chemoprophylaxis should be
carefully directed at high risk travelers when the beneﬁt
of using anti-malarial drug regimens outweighs the risk of
adverse events. The risk for adverse events during the anti-
malarial drugs for prophylaxis is in the range of 30-40%.
Everyone knows that malaria is a disease of low incidence
in America and most of these cases are in topic areas where
tourists only occasionally reach.
A retrospective study conducted on Italian travelers
found that malaria incidence was 1.5/1000 for trips to
Africa, 0.11/1000 for trips to Asia, and 0.04/1000 for trips to
Central and South Americas. Another study among Swedish
travelers found a number four times lesser among travelers
to America (Croft AM. BMJ 2007).
The use of chemoprophylaxis against malaria in this sce-
nario, where contra-indications overlap the beneﬁts, show
us the inadequacy of routinely use of drugs to prevent
malaria in Americas. In a restrict number of cases when the
travelers must stay in remote malaria transmitting areas in
America, for long period o time, we recommend standby
treatment.
doi:10.1016/j.ijid.2010.02.1537
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hoice of Drugs for the Prophylaxis of Malaria in the Amer-
cas
. Magill
Walter Reed Army Institute of Research, Silver Spring, MD,
SA
Preparing a traveler for a trip to the Americas often
ncludes a discussion about the prevention of malaria with
ersonal protection measures to minimize mosquito bites
nd the recommendation to use a drug for chemoprophy-
axis when appropriate. The characteristics of malaria in
he Americas that differ from many other areas of the world
nclude the relatively low transmission rates, the predomi-
ance of vivax malaria in most locations, and the relatively
ide availability of quality medical care for tourists. Use
f all current approved malaria chemoprophylaxis drugs will
e discussed with special emphasis on primaquine, the only
urrently available drug that can prevent vivax malaria.
oi:10.1016/j.ijid.2010.02.1538
urrent issues in multi drug resistant gram-
egatives (Invited Presentation)
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scherichia coli
.-I. Morosini
Ramón y Cajal University Hospital, Madrid, Spain
Escherichia coli is a remarkably versatile organism able
o easily acquire antimicrobial resistance as well as viru-
ence determinants. E. coli is the leading pathogen causing
rinary tract infections and one of the most common organ-
sms implicated in bloodstream infections. Its ubiquity in
he community and hospital setting, together with antibi-
tic overuse, have delineated a scenario in which multidrug
esistant isolates are not infrequent and appear as a fore-
ost challenge for clinicians to achieve therapeutic success.
Beta-lactam resistance owing to the presence of
xtended-spectrum-beta-lactamases (ESBLs) is globally
pread among E. coli, particularly due to CTX-M-type
nzymes, and coexistence of more than one beta-lactamase
n the same isolate has also been observed. Moreover,
o-resistance to non-beta-lactam antimicrobials is a com-
on feature among ESBL-producers as resistance genes
o unrelated antimicrobial compounds such as aminogly-
osides, tetracyclines, sulfonamides, trimethoprim, and
hloramphenicol are simultaneously harboured by conjuga-
ive plasmids carrying transposons and/or integrons where
hese genes are located. The prevalence of certain phy-
ogroups exhibiting these multiresistant phenotypes has
ecently been associated with a genetic island that com-
rises genes encoding antibiotic resistance and virulence
n particular E. coli clones such as the ST131 clone. Con-
omitant resistance to ﬂuoroquinolones due to mutated
opoisomerases in many of these isolates is an alarming real-
ty.
Incidence of E. coli isolates carrying plasmid-AmpC
ephalosporinases is raising in many countries and, although
